About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

you are right i have been in blr since march they are back to what i paid for,but you know i dont collect shares i want a quick profit i do not beleive in tomorrow
remember ult i bought at 0.30/0.32 and sold at 1.36 1.25m that was a good one
look what they are now a year later since ult i bought and sold 20 shares paper profit is no good to me,i like it in the bank....................................................

Shares in EiRx Therapeutics jumped 0.09p to 0.275p after the group unveiled a collaboration agreement with French group bioMerieux. Under the terms of the agreement, the companies will work together to validate the diagnostic and therapeutic potential of candidate tumour markers emerging from their respective cancer research programmes. Both EiRx and bioMerieux undertake research into the expression of genes and proteins within tumour samples from cancer patients, aiming to identify biomarkers associated with the development and progression of the disease.

I think we are going to see a lot of news flow this year and an sp to match.

Notable milestones in 2005/6 include:

Acquisition of oncology company Auvation Ltd

Collaborative research agreement with Merck & Co. Inc. to evaluate EiRx's siRNA delivery technology

Award of a Marie Curie Programme grant from the European Commission, to support development of the company's screening, chemistry and efficacy testing capabilities

Development of the EnPADTM drug screening technology to enable identification of compounds that specifically target cell survival pathways

Filing of patent applications on first series of potential anti-cancer compounds identified using EnPADTM, which target the b-catenin signalling pathway to selectively kill colorectal and breast cancer cells in vitro

Filing of patent application describing a second series of potential anti-cancer compounds identified using EnPADTM

1.2M raised by issue of new shares on 31st March 2006

12th July 2006
CANCER COLLABORATION WITH BIOMERIEUX SA

Director Retires
http://moneyam.uk-wire.com/cgi-bin/articles/200607191251134380G.html

This is a long-term hold or is it.

The company is very much under valued and will very soon be producing compounds that will have an impact on the value of the company. Its all in the interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real

sounds a very committed and sincere CEO - I'm convinced the potential is on the brink of something big. They could do with a bit of PR coaching though when doing these interviews with the yanks it sounds a bit heavy.

ERX on the up punters are hoping for some news Im sure we will see some before the end of the year.

A nice 21% up on speculation of news soon.

34% now!

Make that 44%

forest
OK 44%

dumping started!

The funs over going down a bit of pump and dump I think, this is a long term hold and punters will do well if they are patient.

I got in months ago @ .28 ( the last spike ) long term hold.

forest
M/Cap 3 to 4m this will rocket on any decent news the field in which they are researching is worth billions.

.

Some big buys today

Not a bad finish 11% up with no news.

Gene therapy shrinks melanoma tumors



(MCT)

NEW YORK - Doctors wiped out melanoma by reengineering patients' own cells, marking the first time gene therapy has worked successfully against a cancer and raising hopes that the treatment can eradicate other forms of the disease.

Government scientists took healthy immune cells from patients with advanced forms of the skin cancer and taught the cells to recognize and destroy the cancer cells. Doctors then fed patients the tailor-made fighter cells intravenously, and their tumors gradually shrank.

Just two of the 17 patients in the study are still disease-free a year and a half after the treatment. But doctors said the research proved that the technique could help patients battling many forms of cancer.

"We can now convert normal lymphocytes into cells that can recognize very common cancers like breast, lung, ovary, prostate and so on. We haven't treated those patients yet, but this represents proof that this kind of approach can work," said study author Dr. Steven Rosenberg, chief of surgery at the National Cancer Institute.

The other 15 patients in the study, published in Friday's issue of the journal Science, grew low levels of the reengineered immune cells for at least two months. Since the trial began in December 2004, scientists have developed more advanced gene therapy techniques that could improve the results, Rosenberg said.

"It is totally intriguing," said Dr. Anna Pavlick, director of the NYU Cancer Institute's melanoma program.

But it's too soon to call the therapy a cure, she said.

"They didn't look at survival and they wouldn't be able to in this small group of patients. That's why it's a little bit premature to know how effective this is going to be, but nonetheless it is a treatment that needs to be studied in a larger number of patients," said Dr. Howard Kaufman, director of the tumor immunotherapy program at New York Presbyterian Hospital Columbia.

Melanoma is one of the deadliest and fastest-growing cancers in the United States. An estimated 62,190 people will develop the disease this year, and 7,910 will die of it, according to the American Cancer Society.

---

http://www.duluthsuperior.com/mld/duluthsuperior/news/nation/15414535.htm

sp on the move 21%.